Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.58 |
| ▸ | MEN1 | O00255 | 5/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | HTT | P42858 | 3/20 | 0.52 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.51 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.51 |
| ▸ | GSTP1 | P09211 | 2/20 | 0.49 |
| ▸ | GSTM2 | P28161 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18779425 | 0.94 | MAPT (0.67) | MAPTSMN1; SMN2KMT2AMEN1ALDH1A1 | |
| SCHEMBL18376270 | 0.92 | MAPT (0.62) | MAPTSMN1; SMN2KMT2AMEN1ALDH1A1 | |
| SCHEMBL18779428 | 0.88 | MAPT (0.60) | MAPTSMN1; SMN2KMT2AMEN1ALDH1A1 | |
| SCHEMBL21303710 | 0.86 | MAPT (0.64) | MAPTSMN1; SMN2KMT2AMEN1ALDH1A1 | |
| SCHEMBL18376382 | 0.85 | MAPT (0.66) | MAPTSMN1; SMN2KMT2AMEN1ALDH1A1 | |
| SCHEMBL18779455 | 0.85 | MAPT (0.54) | MAPTSMN1; SMN2KMT2AMEN1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL18763571 | 0.85 | MAPT (0.65) | MAPTSMN1; SMN2KMT2AMEN1ALDH1A1 | |
| SCHEMBL18779427 | 0.82 | MAPT (0.67) | MAPTSMN1; SMN2KMT2AMEN1ALDH1A1 | |
| SCHEMBL18376681 | 0.81 | MAPT (0.57) | MAPTSMN1; SMN2KMT2AMEN1ALDH1A1 | |
| SCHEMBL18376389 | 0.80 | MAPT (0.59) | MAPTSMN1; SMN2KMT2AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170114062-A1 | BENZAMIDE OR BENZAMINE COMPOUNDS USEFUL AS ANTICANCER AGENTS FOR THE TREATMENT OF HUMAN CANCERS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2017-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170114062-A1 | BENZAMIDE OR BENZAMINE COMPOUNDS USEFUL AS ANTICANCER AGENTS FOR THE TREATMENT OF HUMAN CANCERS | ACAT1, ACAT2, NPC1L1 | MAPT 4323/4885SMN1; SMN2 4636/4885KMT2A 1335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.